General Update w.r.t to receipt of letter from promoter under Reg 31(4) of SEBI SAST regulations for the yera ended March 31, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Clinitech Laboratory's promoter and promoter group have filed their mandatory yearly disclosure under SEBI SAST Regulation 31(4). The promoters have confirmed that they have NOT created any encumbrance (pledge) over their shares during FY2025-26. Additionally, Mr. Jagdish Umakant Nayak (Promoter & CMD) acquired 900 additional equity shares on March 30, 2026 (reflected in BENPOS on April 1, 2026). The total promoter holding stands at approximately 14,65,500 shares, including family members across promoter and promoter group categories. All requisite disclosures were filed with relevant authorities within prescribed time limits.
The confirmation of no encumbrance is a positive signal for shareholders as it indicates promoters have not pledged shares, reducing risk of forced selling. The small additional acquisition by the CMD shows continued confidence in the company.